Sennosides
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sennosides: From Constipation Treatment to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Sennosides are stimulant laxatives that are registered and marketed in Singapore as single-ingredient tablets. The TxGNN model predicts they may be effective for hypotrichosis simplex of the scalp, but no clinical trials and no publications currently support this prediction. It is a model-generated signal only, and no plausible mechanism has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data (sennosides are generally used as stimulant laxatives for constipation) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, sennosides are stimulant laxatives. Their active metabolite, rheinanthrone, acts on the colonic mucosa to increase motility and fluid secretion. This is thought to occur through macrophage-derived PGE2 and reduced aquaporin-3 expression.
Nothing in this pathway plausibly connects to hair follicle biology or to a genetic hair-growth disorder. The high TxGNN score reflects graph-based proximity only, and no trial or publication supports it.
The other top predictions show the same pattern:
- Hair-related conditions (congenital hypotrichosis milia, diffuse alopecia areata, alopecia): These overlap heavily and likely represent one correlated signal rather than independent corroboration. Alopecia areata is a T-cell-mediated, JAK/STAT-dependent autoimmune disease, and sennosides have no known activity in that pathway.
- Glaucoma entries (open-angle, primary hereditary, glaucoma 1, and a duplicate open-angle label): These are near-duplicates. Glaucoma management targets intraocular pressure and neuroprotection, and sennosides act locally in the colon with minimal systemic absorption. Chronic laxative use can also cause electrolyte disturbance, which is not beneficial here.
- Esophageal varices (with and without bleeding): The two entries have identical scores, which indicates a duplicated prediction. Varices arise from portal hypertension and are managed with beta-blockers, band ligation, or vasoactive agents.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04731P | SENOKOT TABLET 7.5 mg | Tablet | Not stated in registration data |
| SIN02550P | SENNA TABLET 7.5 mg | Tablet | Not stated in registration data |
Both registrations are valid single-ingredient oral products.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a graph-based model score. There are no clinical trials or publications, and no plausible biological link between a colonic stimulant laxative and hair growth, glaucoma, or esophageal varices. The overlapping predictions look like correlated false positives rather than independent evidence.
To proceed, the following is needed:
- The package insert (warnings and contraindications) from the HSA website, which is a blocking gap for safety screening
- Mechanism of action data for sennosides from DrugBank
- Any preclinical or clinical evidence linking sennosides to hair follicle biology
- Confirmation of the approved indication text for the two Singapore registrations
- Route compatibility analysis (the available oral route versus the likely topical or other route needed for hair or eye conditions)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.